FRAME 04 / FAQ
The questions the search logs keep asking.
Twelve plain-English answers, each one carrying its citation back to the research file. Slightly warmer in register than /research — but the source papers are the same.
What is GHK-Cu?
GHK-Cu is a small molecule made of three amino acids — glycine, histidine, and lysine — bound to one copper(II) ion. The peptide alone is called GHK, and the copper-loaded complex is GHK-Cu (sometimes written Cu-GHK or, in the cosmetic register, Copper Tripeptide-1). Its molecular weight is about 340 Da and the chelation site is held together by the imidazole nitrogen of histidine, the alpha-amino nitrogen of glycine, and a peptide-bond carbonyl oxygen. In water the complex is faintly blue-green — the color the copper(II) coordination geometry gives it.
Where does GHK-Cu come from in the human body?
GHK was first isolated from human plasma by Loren Pickart in the early 1970s. It circulates as an endogenous tripeptide and chelates copper from serum to form GHK-Cu. The detail that has driven most of the subsequent research is that plasma concentration drops roughly threefold across adulthood — measurable in young and old serum side by side — which framed the working question that has anchored the field: does that drop matter, and what does restoring local concentration do?
How does GHK-Cu work at the cellular level?
Two complementary mechanisms. First, it delivers bioavailable copper to enzymes that need it — lysyl oxidase being the headline example, since it crosslinks collagen and elastin into mechanically intact connective tissue. Second, it acts as a transcriptional modulator: Connectivity Map work reports measurable expression changes in roughly 31.2% of analyzed human genes at 1 microM exposure [8], including coordinated movement in caspase, growth-regulatory, and DNA-repair clusters. Downstream you see induction of antioxidant enzymes (SOD1, SOD2, catalase, glutathione peroxidase) [12], MMP / TIMP rebalancing toward controlled matrix remodeling [16], and growth-factor release (bFGF, VEGF, BMP-2, BDNF) from fibroblasts [23].
What does the research say about GHK-Cu and collagen?
The foundational frame is Maquart 1988, in cultured fibroblasts: collagen synthesis stimulation beginning at 10^-12 M and saturating around 10^-9 M, roughly doubling collagen versus non-collagen protein output [1]. The Wegrowski 1992 follow-up showed parallel modulation of glycosaminoglycans and small proteoglycans, including increased decorin mRNA and preferential stimulation of dermatan sulfate and heparan sulfate at the wound site [2]. The Maquart 1993 in vivo rat wound-chamber paper translated those signals into intact tissue, where collagen content rose to 396% of control at day 18 and 538% at day 22 [3].
Does GHK-Cu actually help hair growth?
There are two pieces of research worth knowing. Uno and Kurata 1993 applied a copper-binding peptide analog of GHK (PC1031) topically to fuzzy rats and observed follicular enlargement and a vellus-to-terminal hair shift comparable in magnitude to topical minoxidil [6]. Pyo 2007 added in vitro evidence in cultured human follicular dermal papilla cells: nanomolar tripeptide-copper increased dermal papilla cell proliferation and lengthened in vitro hair shafts [7]. The proposed pathway is Wnt / beta-catenin upregulation in the dermal papilla, consistent with anagen induction. Large human clinical trials of GHK-Cu as a standalone scalp treatment are not in the literature; most translational use is cosmetic scalp-serum formulation.
Is GHK-Cu FDA approved?
No — not as a drug for any therapeutic indication. The cosmetic ingredient Copper Tripeptide-1 is well-established and appears in many topical skincare products. The therapeutic side is different: there is no FDA-approved drug form of GHK-Cu, no FDA-registered Phase 2 or 3 trial of injectable GHK-Cu, and injectable / systemic GHK-Cu was placed on the FDA 503A interim Category 2 compounding list and removed without progression to Category 1, which means it is not currently eligible for 503A pharmacy compounding. Cosmetic use is regulated as a cosmetic; non-topical research-grade use is experimental, unapproved, and sits entirely outside the established cosmetic safety record.
What concentrations of GHK-Cu are used in research?
It depends on the model. Fibroblast cell culture: 10^-12 to 10^-9 M (picomolar to low-nanomolar) for collagen-synthesis stimulation [1]. Connectivity Map gene-expression screens: 1 microM as the standardized screening concentration [8][9][14]. Topical cosmetic formulations: typically 0.05% to 3% w/w in serum, cream, or eye-area products; the 2024 post-laser study used 0.05% gel. Rodent intraperitoneal systemic studies: Zhang 2022 used 0.2, 2, or 20 microg/g body weight per day on alternate days for twelve weeks [11]. Rodent wound chambers: nanomolar local infusion [3]. None of these is a recommendation — they are study attributes.
How is GHK-Cu different from other copper peptides like AHK-Cu?
AHK-Cu (alanyl-histidyl-lysine copper) is a closely related sister tripeptide where the N-terminal glycine of GHK is replaced by alanine. AHK-Cu has been studied primarily for hair-follicle stimulation and sometimes appears in scalp serums alongside GHK-Cu. The two share the chelation geometry and the copper-delivery function, but their gene-expression profiles and clinical literatures are not identical, and AHK-Cu does not have GHK-Cu's depth of fibroblast-collagen and wound-healing data. The two should be read as relatives, not substitutes.
What is GHK-Cu's plasma half-life?
Short. Reported values range from minutes — consistent with rapid aminopeptidase cleavage of the N-terminal glycine — up to roughly 30 to 60 minutes after subcutaneous administration in animal models. Detectable serum levels typically fall below threshold within six to eight hours. The brevity is a large part of why the formulation literature is so active: liposomes, lipid nano-carriers, palmitoylated derivatives (Pal-GHK), and microneedle pretreatment are the dominant strategies for extending bioavailability long enough to be useful.
Why is GHK-Cu paired with liposomes or microneedles?
Because the molecule is hydrophilic and the stratum corneum is a lipid barrier. Free GHK-Cu does not cross intact skin well, and even when it does its half-life works against accumulation. Liposomes encapsulate the tripeptide in a lipid bilayer that can ferry it across the stratum corneum [17][19]. Microneedle pretreatment punches micro-channels that increase transdermal flux dramatically, with the enhancement scaling with insertion depth and application force in a porcine-skin ex vivo permeation study [18]. The 2025 liposomal-delivery review confirms the encapsulation benefit and flags standardized permeation-measurement methods as an open methodological gap [19].
What does GHK-Cu do to gene expression?
Broadly anti-inflammatory, broadly reparative. The Connectivity Map work reports greater than 50% expression change in roughly 31.2% of analyzed human genes at 1 microM, with coordinated movement in caspase, growth-regulatory, and DNA-repair clusters [8]. A separate paper reports reversal of about 70% of genes in a 54-gene signature for aggressive metastasis-prone colon cancer [9]. Other Connectivity Map readings have flagged GHK as a candidate for reversing emphysematous lung gene-expression signatures [10] and as a profile of interest for neurodegenerative-condition research [14]. One caveat worth keeping: the magnitude claims rest mostly on Connectivity Map and single-concentration microarray data and have not been comprehensively replicated across independent platforms. The direction is well attested; the absolute gene count is less so.
Is GHK-Cu safe?
In the cosmetic register the safety record is unremarkable — Copper Tripeptide-1 is widely used and well-tolerated in topical formulations. The theoretical concerns live elsewhere. Copper free in solution can be cytotoxic at higher concentrations, so the chelated GHK form matters: the peptide holds the ion in a coordinated geometry that delivers Cu(II) safely at low doses, but free-copper overload remains a concern with poor-quality formulations. Commercial 'copper peptide' products vary widely in purity, copper-loading state (apo- vs holo-peptide), and formulation pH. The research-grade material discussed across this archive is
Why does GHK-Cu look blue-green in solution?
Because the copper(II) coordination geometry inside the chelation site absorbs in the red end of the visible spectrum and transmits in the blue-green. The same physical principle is responsible for the color of copper sulfate solutions and for the patina on weathered bronze — bound Cu(II) in an octahedral or square-planar coordination environment generates a characteristic blue-green absorption profile. In a working lab, the color is also a rough sanity check: pale blue-green suggests the chelation is intact, while colorless or yellowed solution suggests degradation, copper loss, or oxidation. The faded teal that anchors this site's palette is a small visual nod to that physical fact.
What is the difference between GHK and GHK-Cu?
GHK is the free tripeptide — glycine, histidine, lysine, with no copper bound. GHK-Cu (sometimes written Cu-GHK) is the same tripeptide carrying one chelated Cu(II) ion. The free peptide can be synthesized and stored apo (no copper); it picks up copper readily from biological fluids because the chelation affinity is high. Most of the research that matters — the fibroblast collagen work, the wound-healing data, the cosmetic-clinical trials — refers to the copper-loaded complex. When a paper writes 'GHK' without qualification, the context (in vivo, biological fluid present) typically means the molecule is rapidly chelating endogenous copper and acting as GHK-Cu in practice. Apo-peptide and holo-peptide are not interchangeable in cosmetic formulation, though, and product variability on this axis is one of the known confounds in cross-product comparison.